Subhashis Banerjee - 27 Aug 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Chief Medical Officer
Issuer ticker: ARTV
Reported as of: 27 Aug 2026
Net transaction value: -$98,736
SEC form: 4
Accepted by SEC: 31 Aug 2026, 19:06:27 UTC
Prior SEC filing: 19 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Cronauer, Attorney-in-Fact

Key filing fact

Subhashis Banerjee filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 31 Aug 2026.

Key facts

This page summarizes Subhashis Banerjee's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Aug 2026, 19:06.

Change

Previous filing in this sequence was filed on 19 Aug 2026.
Current net transaction value: -$98,736.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002065633 Primary reporting owner

Banerjee Subhashis

Relationship: Chief Medical Officer
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Andrew Cronauer, Attorney-in-Fact
Signature date: 31 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,306
Change %: +3.7%
Price: $1.92^*
Shares after: 150,269
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

ARTV transaction

Common Stock

Sale

Transaction value: $98,736
Shares: -8,222
Change %: -5.5%
Price: $12.01
Shares after: 142,047
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARTV transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -5,306
Change %: -6.7%
Price: $0.000000^*
Shares after: 74,265
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,306
Exercise price: $1.92
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

Footnote F2

The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.